854584-01-3

Basic information

• Product Name: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-
• Synonyms: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-;6-broMo-1,2-dihydroquinoxalin-2-ol;6-Bromo-3,4-dihydroquinoxalin-2(1H)-one;6-BroMo-3,4-dihydro-1H-quinoxalin-2-one
• CAS NO: 854584-01-3
• Molecular Formula: C₈H₇BrN₂O
• Molecular Weight: 227.05798
• Mol File: 854584-01-3.mol

Chemical Properties

• Appearance: /
• Density: 1.610±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-(854584-01-3)
• EPA Substance Registry System: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-(854584-01-3)

Safety Data

• Hazardous Substances Data: 854584-01-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2(1H)-Quinoxalinone, 6-broMo-3,4-dihydrois utilized as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties allow for the development of new drugs with potential therapeutic applications.
Used in Antiviral Applications:
In the field of antiviral research, 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydrois used as a compound with potential antiviral properties. Its ability to interact with viral components and inhibit viral replication makes it a valuable candidate for the development of new antiviral drugs.
Used in Anticancer Applications:
2(1H)-Quinoxalinone, 6-broMo-3,4-dihydrois employed as an anticancer agent, leveraging its potent biological activities to target and inhibit the growth of cancer cells. Its unique structure allows for specific interactions with cellular components, potentially leading to the development of novel cancer therapies.
Used in Antibacterial Applications:
In the context of antibacterial research, 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydrois used for its potential to combat bacterial infections. Its ability to interfere with bacterial processes and inhibit bacterial growth positions it as a candidate for new antibacterial agents.
Used in Research and Drug Development:
2(1H)-Quinoxalinone, 6-broMo-3,4-dihydrois a valuable compound in scientific research and drug development. Its unique chemical and biological properties make it an attractive subject for studies aimed at understanding its mechanisms of action and potential applications in medicine.

Upstream product

• 854583-92-9 N-(2-amino-4-bromophenyl)-2-chloroacetamide 
• 875-51-4 4-Bromo-2-nitroaniline 
• 854583-85-0 N-(4-bromo-2-nitrophenyl)-2-chloroacetamide 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 1486183-97-4 ethyl 2-(5-brom9-2-nitro-anilino)acetate 

Downstream Products

• 305790-79-8 6-bromo-4-methyl-3,4-dihydroquinoxalin-2(1H)-one 
• 55687-34-8 6-bromoquinoxalin-2(1H)-one 
• 55687-02-0 6-bromo-2-chloro-quinoxaline 

Relevant articles and documents

Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors

BRD4 plays a key role in transcriptional regulation. Recent biological and pharmacological studies have demonstrated that bromodomain-containing protein 4 (BRD4) is a viable drug target for cancer treatment. In this study, we synthesized a series of dihydroquinoxalinone derivatives and evaluated their BRD4 inhibitory activities, obtaining compound 5i with IC50 value of 73?nM of binding activity in BRD4(1) and 258?nM of cellular activity in MV-4-11 cancer cell lines. Docking studies were performed to explain the structure-activity relationship. Based on its potent biochemical and anti-proliferative activity, the novel BRD4 inhibitor compound 5i, is a promising lead compound for further investigation.

HETEROCYCLIC COMPOUNDS

The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof has an BET family protein inhibitory action, and is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, idiopathic pulmonary fibrosis, psoriasis, atopic dermatitis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, systemic lupus erythematosus etc.), cancer and the like.

Heteroatom insertion into 3,4-dihydro-1 H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase

Aldosterone synthase (CYP11B2) catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone. CYP11B2 is regarded as a new target for several cardiovascular diseases which are associated with chronically elevated aldosterone levels such as hypertension, congestive heart failure and myocardial fibrosis. In this paper, we optimized heterocycle substituted 3,4-dihydropyridin-2(1H)-ones as CYP11B inhibitors by systematic introduction of heteroatoms and by bioisosteric exchange of the lactame moiety by a sultame moiety. The most promising compounds regarding inhibition of human CYP11B2 and selectivity versus human enzymes CYP11B1, CYP17, and CYP19 were tested for inhibition of rat CYP11B2. Thus, we discovered compounds 4 and 9 which show potent inhibition of hCYP11B2 (IC50 1 nM) and the corresponding rat enzyme (4: 64%, 9: 51% inhibition, at 2. 2 μM).

Inhibitors of the Human Aldosterone Sythase CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11β-hydroxylase (CYP11B1) with these compounds.

6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1 ).